Psychiatry Advisor

Expert Insights: Can GLP-1 Drugs Protect the Kidneys From Lithium-Induced Damage in Bipolar Disorder?

Dr McIntyre and colleagues share new insight on how GLP-1 receptor agonists may protect against lithium-induced kidney damage in patients treated for bipolar disorder.
Becker's Hospital Review

FDA OKs new pill for schizophrenia, bipolar disorder

The FDA has approved Bysanti (milsaperidone) tablets for the treatment of bipolar I disorder and schizophrenia in adults. The drug is indicated as a first-line therapy for acute manic or mixed ...
Seeking Alpha

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New ...

WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a ...
The Manila Times

NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and ...